[{"id":"2dd784c3-2556-4e8f-858c-e43a2f1be9da","acronym":"realMIND","url":"https://clinicaltrials.gov/study/NCT04981795","created_at":"2021-07-29T14:53:08.563Z","updated_at":"2024-07-02T16:34:26.241Z","phase":"","brief_title":"realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL","source_id_and_acronym":"NCT04981795 - realMIND","lead_sponsor":"Incyte Corporation","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 translocation • BCL2 translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-06-13"},{"id":"82776520-b06e-46e0-b799-6acc9cecb384","acronym":"","url":"https://clinicaltrials.gov/study/NCT05615636","created_at":"2022-11-14T14:58:16.761Z","updated_at":"2024-07-02T16:34:36.912Z","phase":"Phase 2","brief_title":"A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL","source_id_and_acronym":"NCT05615636","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/28/2023","start_date":" 04/28/2023","primary_txt":" Primary completion: 08/19/2025","primary_completion_date":" 08/19/2025","study_txt":" Completion: 08/19/2027","study_completion_date":" 08/19/2027","last_update_posted":"2024-06-10"},{"id":"597f3d3b-7b1b-4903-87c4-f3117fd83b5e","acronym":"topMIND","url":"https://clinicaltrials.gov/study/NCT04809467","created_at":"2021-03-22T11:52:17.035Z","updated_at":"2024-07-02T16:34:37.699Z","phase":"Phase 1/2","brief_title":"A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT04809467 - topMIND","lead_sponsor":"Incyte Corporation","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/16/2021","start_date":" 09/16/2021","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-06-06"},{"id":"f7c3ddbe-249b-4c4f-95d9-1395355fc59e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05788289","created_at":"2023-03-28T14:05:17.881Z","updated_at":"2024-07-02T16:35:12.394Z","phase":"Phase 2","brief_title":"A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma","source_id_and_acronym":"NCT05788289","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2024-03-28"},{"id":"1c914bb8-683d-42e3-92d6-709320ffc521","acronym":"frontMIND","url":"https://clinicaltrials.gov/study/NCT04824092","created_at":"2021-04-01T17:52:25.384Z","updated_at":"2024-07-02T16:35:16.935Z","phase":"Phase 3","brief_title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","source_id_and_acronym":"NCT04824092 - frontMIND","lead_sponsor":"MorphoSys AG","biomarkers":" ALK • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" ALK positive • CD20 positive • BCL6 rearrangement","tags":["ALK • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • CD20 positive • BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Monjuvi (tafasitamab-cxix) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 899","initiation":"Initiation: 05/11/2021","start_date":" 05/11/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-03-01"},{"id":"e5397458-5d87-4f9f-b7a0-005976446ec3","acronym":"V-MIND","url":"https://clinicaltrials.gov/study/NCT05910801","created_at":"2023-06-20T14:07:47.501Z","updated_at":"2024-07-02T16:35:23.016Z","phase":"Phase 2","brief_title":"Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT05910801 - V-MIND","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" CD19 • CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • CD19 expression • Chr t(11;14)(q13;q32)","tags":["CD19 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • CD19 expression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • lenalidomide • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/04/2024","start_date":" 01/04/2024","primary_txt":" Primary completion: 12/30/2029","primary_completion_date":" 12/30/2029","study_txt":" Completion: 12/30/2030","study_completion_date":" 12/30/2030","last_update_posted":"2024-01-18"},{"id":"f4f696be-e6d4-4c32-b4f1-9072ee9d48a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01685008","created_at":"2023-02-23T20:00:56.004Z","updated_at":"2024-07-02T16:35:30.262Z","phase":"Phase 2a","brief_title":"Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)","source_id_and_acronym":"NCT01685008","lead_sponsor":"MorphoSys AG","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Monjuvi (tafasitamab-cxix)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 04/23/2013","start_date":" 04/23/2013","primary_txt":" Primary completion: 04/06/2022","primary_completion_date":" 04/06/2022","study_txt":" Completion: 04/06/2022","study_completion_date":" 04/06/2022","last_update_posted":"2023-11-06"},{"id":"cd985479-09e0-4f1f-9b27-f6831cbc702a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943496","created_at":"2023-07-13T18:10:41.453Z","updated_at":"2024-07-02T16:35:30.466Z","phase":"Phase 1","brief_title":"Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT05943496","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib) • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/02/2023","start_date":" 10/02/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-11-03"},{"id":"e661d003-b9bf-4c80-870d-6f6cf37b5b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821088","created_at":"2023-04-20T14:03:45.424Z","updated_at":"2024-07-02T16:35:30.742Z","phase":"Phase 2","brief_title":"Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma","source_id_and_acronym":"NCT05821088","lead_sponsor":"David Bond, MD","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-01"},{"id":"883c093f-d2f2-4bdb-a6df-2c4fb2930bc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05890352","created_at":"2023-06-06T14:06:56.792Z","updated_at":"2024-07-02T16:35:34.556Z","phase":"Phase 2","brief_title":"Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment","source_id_and_acronym":"NCT05890352","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" MYC • BCL2 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Brukinsa (zanubrutinib) • Tazverik (tazemetostat) • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 09/26/2023","start_date":" 09/26/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2023-10-05"},{"id":"33ca19b0-df14-4b3c-a2b7-6d51bb4a245b","acronym":"VERLen","url":"https://clinicaltrials.gov/study/NCT04974216","created_at":"2021-07-23T13:52:23.347Z","updated_at":"2024-07-02T16:35:53.036Z","phase":"Phase 2","brief_title":"Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older","source_id_and_acronym":"NCT04974216 - VERLen","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" BCL2 • CD20 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 12/20/2021","start_date":" 12/20/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-03-17"},{"id":"cbc672e1-3f8e-43b2-860d-b6594a826911","acronym":"","url":"https://clinicaltrials.gov/study/NCT04607772","created_at":"2021-01-29T07:21:32.870Z","updated_at":"2024-07-02T16:35:57.084Z","phase":"Phase 1/2","brief_title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04607772","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • lenalidomide • oxaliplatin • Xpovio (selinexor) • bendamustine • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Suspended","enrollment":" Enrollment 350","initiation":"Initiation: 11/18/2020","start_date":" 11/18/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-01-25"},{"id":"6ff06964-4a4d-4f6c-8623-c8cc6737eeca","acronym":"","url":"https://clinicaltrials.gov/study/NCT04882163","created_at":"2021-05-11T11:53:08.827Z","updated_at":"2024-07-02T16:36:23.460Z","phase":"Phase 1b/2","brief_title":"Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma","source_id_and_acronym":"NCT04882163","lead_sponsor":"Celgene","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" ALK positive • BCL6 rearrangement","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • dexamethasone • bendamustine • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • iberdomide (CC-220)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/10/2021","start_date":" 10/10/2021","primary_txt":" Primary completion: 04/08/2026","primary_completion_date":" 04/08/2026","study_txt":" Completion: 04/07/2029","study_completion_date":" 04/07/2029","last_update_posted":"2021-10-05"}]